Bayer’s Kerendia (finerenone) has secured FDA approval for treatment of patients with chronic kidney disease (CKD) associated with type 2 diabetes.

Kerendia is a nonsteroidal mineralocorticoid receptor antagonist intended to slow CKD progression, reduce the risk of kidney failure, heart attack, heart failure hospitalization and cardiovascular death.

The FDA approval comes after a phase 3 trial of 5,674 patients in which Kerendia treatment resulted in a lower risk of CKD progression and cardiovascular events than placebo.

The incidence of CKD is as high as 40 percent among type 2 diabetes patients.